Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angeion

This article was originally published in The Gray Sheet

Executive Summary

First preclinical implantation of the Sentinel 2000 fourth- generation implantable cardioverter defibrillator is successfully performed, the Minneapolis, Minnesota-based company reports. Angeion plans the first human implantation of the device in Europe by the end of the summer and hopes to submit an investigational device exemption to FDA six to eight months later. Angeion has also been allowed two patents relating to the Sentinel: one for the "optimized" biphasic waveform and one for its "energy steering method," which allows for more uniform energy distribution throughout the heart "regardless of the type and position of the electrodes," the company says
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel